Life Medical Sciences Launches Drug Delivery Development Program
12 Maio 2004 - 9:30AM
PR Newswire (US)
Life Medical Sciences Launches Drug Delivery Development Program
Update on REPEL-CV(TM) Pivotal Clinical Trial OCEANPORT, N.J., May
12 /PRNewswire-FirstCall/ -- During a presentation today at the
Rodman & Renshaw TechVest Global Healthcare Conference in
London, Robert P. Hickey, President & CEO of Life Medical
Sciences, Inc. (BULLETIN BOARD: CHAI) , will announce that the
Company has undertaken a development program intended to provide
cardiac surgeons with the first ever localized drug delivery
product intended to prevent the onset of surgically-induced atrial
fibrillation. Approximately one third of patients undergoing open
heart surgery develop atrial fibrillation, or irregular heart beat,
resulting from the trauma of the surgical procedure. This
complication is currently treated with systemic drug delivery and
requires increased patient monitoring and results in delayed
discharge from the hospital. Similar to drug eluding stents, the
drug would be impregnated into the Company's REPEL-CV bioresorbable
film which is designed to be placed on the surface of the heart
during the surgical procedure. The objective is to deliver the drug
to the heart tissue as the film resorbs, thus eliminating the need
for expensive systemic drug delivery. Mr. Hickey will also state
that patient enrollment in the multi-center, pivotal clinical trial
for REPEL-CV bioresorbable adhesion barrier in cardiac surgery is
proceeding on schedule with a targeted completion date for the
trial still anticipated in mid-2005. Life Medical Sciences, Inc. is
a biomaterials company engaged in the development and
commercialization of innovative and cost-effective medical devices.
The Company is developing a broad range of bioresorbable polymer
products to prevent/reduce post-operative adhesion formation.
Certain statements in this Press Release constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of the Company, or industry results, to be materially
different from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Reference
is made to the Company's Annual Report on Form 10-KSB for the year
ended December 31, 2003 for a description of some of these risks
and uncertainties. DATASOURCE: Life Medical Sciences, Inc. CONTACT:
Robert P. Hickey of Life Medical Sciences, Inc., +1-732-728-1769,
Copyright